The Platform Group’s Growth Story Faces a Skeptical Market as AEP Deadline Nears

Despite 65% EBITDA jump and €728M revenue, TPG shares plummet 50% from highs as market awaits AEP deal closure and Q1 results.

The disconnect at The Platform Group (TPG) could hardly be starker. On one side of the ledger, the software and platform company delivered a 39% revenue jump to €728 million last year, pushed adjusted EBITDA 65% higher to €55 million, and saw cash flow of almost €60 million exceed that earnings figure. Net profit per share surged to €2.26. On the other side, the stock has halved from its mid-February high of €5.50 and changed hands at €2.78 on Monday before sliding another 5% to €2.72 on Tuesday — not far above a 52-week low of €2.53 hit just last week.

That extreme price action reflects a market struggling to get comfortable with the near-term outlook. With a 30-day annualized volatility reading of more than 137% (some measures put it at 138%), trading in TPG shares has become a white-knuckle affair. The equity now sits nearly 15% below its 50-day moving average, a technical signal that bears have seized control.

At the heart of the nervousness is the pending acquisition of AEP GmbH, a pharmaceutical wholesaler that is set to transform the group’s business model. Integration is scheduled to wrap up by the end of May, and the closing details — including the precise mix of debt and equity financing — are expected to be disclosed by that same deadline. Once the deal is fully consolidated, management’s pro-forma targets call for annual revenue of roughly €2 billion, a gross merchandise value (GMV) of €3.2 billion, and adjusted operating earnings of up to €100 million.

Until that deal closes, however, TPG must prove it can sustain momentum on its own. For the current year, the board has reaffirmed the guidance issued in January: a net revenue target of €1.0 billion, GMV of €1.7 billion, and adjusted EBITDA in a range of €70 million to €80 million. Those numbers reflect the existing portfolio, which was expanded last year through eleven strategic bolt-on acquisitions and a new “Optics & Hearing” segment. The active partner base has grown to over 16,600, and the equity ratio has climbed above 48%, underscoring a balance sheet that is in far better shape than a year ago.

The next major test arrives on May 27, when first-quarter figures are due. In the accompanying analyst call, the executive team will need to demonstrate that organic growth is still accelerating — even without the pharmaceutical revenue stream. The software-driven platform model is widely viewed as highly scalable, but any softness in the opening quarter could trigger another probe of the recent lows.

For now, the market is taking a wait-and-see posture, punishing each drop and refusing to reward a fundamentally strong set of 2025 numbers. The AEP transaction holds the potential to double revenue and boost margins, but until financing terms and integration milestones are clear, the stock’s wild swings are likely to continue.